NCT04376554View on ClinicalTrials.gov

Effect of Tebipenem on Normal Human Intestinal Microbiota

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

April 6, 2021

Study Completion Date

April 6, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

TBPM-PI-HBr

TBPM-PI-HBr (2 x 300mg tablets) PO q8h \[±1 hour\] for 10 days

DRUG

amoxicillin-clavulanate

amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h \[±1 hour\] for 10 days

Trial Locations (1)

Unknown

Karolinska University Hospital, Huddinge

Sponsors

Lead Sponsor

Spero Therapeutics
All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Spero Therapeutics

INDUSTRY

NCT04376554 - Effect of Tebipenem on Normal Human Intestinal Microbiota | Biotech Hunter | Biotech Hunter